Evidence map›Paper›PMID 40617532›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2025

Hyalinizing Clear Cell Carcinoma of the Head and Neck: A Multicenter Retrospective Study of 87 Cases Focusing on Prognostic Pathologic Features and Grading Scheme.

Bin Xu, Kartik Viswanathan, Marie Barbesier, Alexander Ladenheim, Cristina R Antonescu, Ronald Ghossein, Dan Lubin, Kelly Magliocca, Sayed Matar, Michael W Mikula and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Bin XuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Kartik ViswanathanDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Marie BarbesierDepartment of Pathology, Centre Hospitalier Universitaire Vaudois, Switzerland.
Alexander LadenheimDepartment of Anatomic Pathology, Yale School of Medicine, New Haven, Connecticut.
Cristina R AntonescuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Ronald GhosseinDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Dan LubinDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Kelly MaglioccaDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Sayed MatarDepartment of Anatomic Pathology, Yale School of Medicine, New Haven, Connecticut.
Michael W MikulaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Isabella Tondi RestaDepartment of Pathology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Dibisha RoyDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Soo Yeon SohnDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
Anuj VermaDepartment of Anatomic Pathology, Yale School of Medicine, New Haven, Connecticut.
Manju L PrasadDepartment of Anatomic Pathology, Yale School of Medicine, New Haven, Connecticut.
Lisa RooperDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Margaret Brandwein-WeberDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
Zubair BalochDepartment of Pathology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Nora KatabiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: katabin@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Hyalinizing clear cell carcinoma (HCCC) is a salivary gland carcinoma characterized by the presence of clear and eosinophilic cells within a hyalinized stroma and the EWSR1 rearrangement. Aiming to identify prognostic factors and establish a grading system, we herein conducted a detailed clinicopathology review of a large retrospective cohort of 87 HCCCs from 7 tertiary centers. Most HCCCs (91%) originated from minor salivary glands, although major salivary glands were affected in 8%. The most common sites were base of tongue, palate, nasopharynx, and maxilla. Eosinophilic cells were more prevalent than clear cells. Histologic features included intraosseous component (19%), perineural invasion (48%), lymphovascular invasion (LVI, 16%), nuclear pleomorphism (14%), tumor necrosis (26%), and a mitotic index (MI) ≥ 5/2 mm

Indexed as

Adenocarcinoma, Clear CellHead and Neck NeoplasmsSalivary Gland NeoplasmsAdolescentAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansHyalinMaleMiddle AgedNeoplasm GradingPrognosisRetrospective StudiesEWSR1 translocationhyalinizing clear cell carcinomaprognosissalivary gland carcinoma

Identifiers

PMID40617532
PMCPMC12323664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.